Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
Status:
Completed
Trial end date:
2018-04-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose and characterize the
safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with
trametinib alone in participants with metastatic or unresectable melanoma with BRAF-mutation
positive or wild-type (WT) BRAF, respectively.